NCT06543511

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes.

Detailed description

The purpose of this prospective, non-randomized, non-therapeutic, single arm study is to determine the feasibility and benefit of performing genetic testing for all participants with a blood cancer diagnosis regardless of clinical suspicion. Research study procedures include screening for eligibility, in-clinic visits, questionnaires, and skin punch biopsies. Participants will receive germline genetic testing with a comprehensive hereditary cancer gene panel. It is expected that about 200 individuals with blood cancer will take part in this research study.

Conditions

• Myeloid Malignancy
• Myeloid Malignancies
• Blood Cancer
• Blood Cancers

Interventions

Type	Name	Description
OTHER	Genetic Blood Test	Germline genetic testing using skin fibroblasts

Timeline

• Start date: 2024-07-29
• Primary completion: 2028-07-01
• Completion: 2029-07-01
• First posted: 2024-08-09
• Last updated: 2024-11-22